Reinventing Medicine

with Protein Degradation

Our Company

Expanding the Range of
Treatable Disease

Kymera is committed to advancing cutting-edge science to develop a new generation of medicines that address critical health problems and dramatically improve patients’ lives by targeting the fundamental drivers of disease.

Redefining New Treatment Paradigms

Targeted protein degradation is a disease-agnostic modality fundamentally changing how drugs can work, creating unprecedented opportunities to treat a wide variety of diseases.

Our Company

Our team is committed to delivering life-changing medicines with passion, focus, and a sense of urgency.

Our Pipeline

Driven by our powerful and highly productive drug discovery engine, we are delivering a pipeline of first-in-class therapeutics designed to transform the standard of care for patients.

Recent News
July 9, 2024
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
July 8, 2024
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
June 14, 2024
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Our Team

Kymera is building a fully integrated medicines company to redefine disease treatment. Learn more about how you can help shape the future of medicine.